Sortera bio

Executive Summary

Sortera Bio is a London-based private biotechnology company founded in 2021 that leverages artificial intelligence and machine learning to transform biologics drug discovery. Its proprietary Deep Screening technology generates massive sequence-function datasets, enabling AI models to rapidly identify and optimize therapeutic antibodies and other protein-based drugs with unprecedented speed and precision. By combining high-throughput experimental data with advanced computational algorithms, Sortera aims to de-risk and accelerate the development of next-generation biologics, addressing the industry's need for more efficient discovery platforms. The company operates at the intersection of AI and biologics, a high-growth area attracting significant investor interest. While currently in early stages with no disclosed funding or pipeline, Sortera's approach has the potential to significantly reduce the time and cost of bringing biologic drugs to market, positioning it as a promising player in the AI-driven drug discovery landscape.

Upcoming Catalysts (preview)

• Q4 2026Series A or B Funding Round Announcement80% success
• Q1 2027Pharmaceutical Partnership or Collaboration60% success
• Q2 2027Publication of Deep Screening Validation Data70% success